I’ve spent a career watching how global systems rely on seamless movement to survive. Much like the SWIFT banking networks I once managed—where friction in one node slows the entire flow—capital in the pharmaceutical world follows the path of least … Continue reading German Pharma’s Atlantic Tilt: Why the “Starting Line” is Moving to America